Drugs, chemicals, non-coding RNAs or their inhibitors as potential treatments, or as diagnostic markers | Proposed Basic action in brief | Sections in paper and related figures |
Irisin (synthetic compound of this hormone has been achieved in small amount) | Target the AMPK-mTOR1 pathway | (3.3) |
Gemcitabine and nimotuzumab | As monoclonal antibody of epidermal growth factor | (4.5) |
Phenols, sulfonamides, and their analogs | Target Ras protein in Ras-Raf-Erk pathway | (4.5) |
Abemaciclib | To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; drug also applied to treat pancreatic cancers | (5.2) |
DD44mT (di-2-pyridylketone 4,4-dimthyl-3-thiosemicarbazone), Fe chelator | Activates protein Ndrg1 and hence cyclic-dependent kinase inhibitor p21 | (5.3), Figure 7, Figure 9 |
DFO (desferrioxamine), Fe chelator | As above | As above |
311(2-hydroxy-1-naphthylal dehydro-isonicotinoyl hydroazone) | As above | As above |
RC68, a humanized anti-EGFR monoclonal antibody, as an antibody-drug conjugate | A monoclonal antibody chemically linked to a drug that is toxic when the ingredient is released inside the target cell. | (8.5), Figure 7, Figure 9 |
APX3330, compound | Regulate activities of hypoxia-inducible factor 1 α (HIF-1 α), NF-κB, and function of Jak-STAT3 pathway | (9.4), Figure 2, Figure 7, Figure 10 |
SLC-0111, compound | As above | (9.4) |
Combination of cyclopamine and paclitaxel delivered by nan-particles | As an inhibitor of the Hedgehog pathway | (10.3), Figure 11 |
RO4929097, compound | As an inhibitor of γ-secretase in Notch pathway | (3.2), Figure 12 |
ATRA (Vitamin A) | Attenuate endothelial-mesenchymal transition of stellate cell | (18.1), Figure 13 |
Tocotrienols β, γ, δ (sub-family of vitamin E) | Suppress NF-κB mediated inflammation | (18.2), Figure 10 |
Calcipotriol (Ca), Vitamin D receptor ligand | Reduce inflammation and fibrosis | (18.3) |
PEGPH20 (Pegvorhyaluronidase alfa) together with other anti-cancer drugs | Reduce the concentration of interstitial fluid in tumor stroma | (18.4), Figure 17 |
Micro RNA 96 mimics | Target Ras-Raf-Mek-Erk pathway | (19.2), Figure 3 |
Micro RNA 34 mimics | Target Notch pathway and target anti-apoptotic Bcl-2 protein | (19.3), Figure 12 |
Micro RNAs 21 plus 221 mimics | Treat metastatic pancreatic cancer cells in general | (19.4) |
Micro RNA 146a mimics | Downregulates EGFR, downregulates NF-κB, upregulates PTEN | (19.5), Figure 2, Figure 7, Figure 9, Figure 10 |
Antisense non-coding circular RNA IARS mimics | Reducing endothelial permeability to attenuate cancer invasion | (20.2) |
Antisense non-coding circular RNA LDLRAD3 mimics | Treats pancreatic cancer cells in general | (20.3) |
Antisense non-coding circular RNA_100782 | Targets IL6-Jak-STAT3 pathway | (20.4), Figure 7 |